Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 14/20 | 0.63 |
| ▸ | HTR7 | P34969 | 12/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050179 | 0.89 | HTR2B (0.63) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12050156 | 0.79 | PTPRC (0.57) | CES1PABPC1DNMT1 | |
| SCHEMBL4923552 | 0.78 | HTR2B (1.00) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12050181 | 0.76 | HTR2B (0.64) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL14087443 | 0.75 | HTR2B (0.94) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL4920346 | 0.73 | HTR2B (0.74) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL24573355 | 0.73 | PTPRC (0.57) | CES1PABPC1DNMT1 | |
| SCHEMBL12050184 | 0.72 | HTR2B (0.68) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12050183 | 0.71 | HTR2B (0.60) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL6995480 | 0.71 | S100A4 (0.53) | HTR2BHTR7CES1PABPC1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | HTR2B 1/4885HTR7 2/4885DRD2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.